Clinical trialNCT04683679RecruitingPhase 2Interventional

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

SponsorMemorial Sloan Kettering Cancer CenterEnrollment34Breast CancerMetastatic Breast CancerTNBC - Triple-Negative Breast CancerTriple Negative Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to find out whether adding pembrolizumab, with or without olaparib, to standard radiation therapy is a safe and effective treatment for metastatic breast cancer, , and to see whether the study treatment is better than, the same as, or worse than the usual approach (radiation therapy alone).

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Atif Khan, MD
Memorial Sloan Kettering Cancer Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Memorial Sloan Kettering Basking Ridge (limited Protocol Activities)
Basking Ridge, New Jersey, United States
Recruiting
Memorial Sloan Kettering Monmouth (limited Protocol Activities)
Middletown, New Jersey, United States
Recruiting
Memorial Sloan Kettering Bergen (limited Protocol Activities)
Montvale, New Jersey, United States
Recruiting
Memorial Sloan Kettering Commack (limited Protocol Activities)
Commack, New York, United States
Recruiting
Memorial Sloan Kettering Westchester (limited Protocol Activities)
Harrison, New York, United States
Recruiting
Memorial Sloan Kettering Cancer Center (all Protocol Activities)
New York, New York, United States
Atif Khan, MD
Recruiting
Memorial Sloan Kettering Nassau (all Protocol Activities)
Uniondale, New York, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Olaparib →Pembrolizumab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 21 Apr 2021
Primary completion: 31 Jan 2027
Completion: 31 Jan 2027
Last update posted: 17 Feb 2026
Registered enrollment: 34
Registry id: NCT04683679

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.